Ondansetron
- Generic Name
- Ondansetron
- Brand Names
- Zofran, Zuplenz
- Drug Type
- Small Molecule
- Chemical Formula
- C18H19N3O
- CAS Number
- 99614-02-5
- Unique Ingredient Identifier
- 4AF302ESOS
- Background
A competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties.
...
- Indication
In the adult patient population:
i) orally administered ondansetron tablets and orally disintegrating tablets (ODT) are indicated for:
- the prevention of nausea and vomiting associated with emetogenic cancer chemotherapy, including high dose (ie. greater than or equal to 50 mg/m2) cisplatin therapy, and radiotherapy, and
...
- Associated Conditions
- Chemotherapy-Induced Nausea and Vomiting, Cholestatic pruritus, Post Operative Nausea and Vomiting (PONV), Radiation-Induced Nausea and Vomiting, Uremic Pruritus, Severe Hyperemesis gravidarum
- Associated Therapies
- -
Efficacy & Safety of the Oral Neurokinin-1 Antagonist, Aprepitant, in Combo With Ondansetron & Dexamethasone in Patients Undergoing Auto Peripheral Blood Stem Cell Transplantation
- Conditions
- Interventions
- First Posted Date
- 2006-04-14
- Last Posted Date
- 2013-05-24
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 48
- Registration Number
- NCT00314743
- Locations
- 🇺🇸
Washington University School of Medicine, St. Louis, Missouri, United States
Aprepitant in Preventing Nausea and Vomiting in Patients Who Are Undergoing a Stem Cell Transplant
- Conditions
- Interventions
- First Posted Date
- 2005-11-04
- Last Posted Date
- 2017-05-09
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 40
- Registration Number
- NCT00248547
- Locations
- 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States
Study for The Prevention Of Nausea in Cancer Patients Receiving Highly Emetogenic Cisplatin Based Chemotherapy
- Conditions
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2010-05-10
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 492
- Registration Number
- NCT00169572
- Locations
- 🇨🇳
GSK Investigational Site, Tao Yuan County, Taiwan
Patient Education in Preventing Nausea and Vomiting in Cancer Patients Receiving Chemotherapy
- Conditions
- First Posted Date
- 2004-06-09
- Last Posted Date
- 2013-03-05
- Lead Sponsor
- University of Rochester
- Registration Number
- NCT00005994
- Locations
- 🇺🇸
Hackensack University Medical Center, Hackensack, New Jersey, United States
🇺🇸University of Rochester Cancer Center, Rochester, New York, United States
🇺🇸CCOP - Southeast Cancer Control Consortium, Winston-Salem, North Carolina, United States
Study of Aprepitant (MK-0869) for Chemotherapy-Induced Nausea and Vomiting (CINV) in Adolescent Participants (MK-0869-097)
- Conditions
- Interventions
- First Posted Date
- 2004-04-02
- Last Posted Date
- 2014-08-05
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 50
- Registration Number
- NCT00080444
Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment
- Conditions
- Interventions
- First Posted Date
- 2004-03-25
- Last Posted Date
- 2016-07-06
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 100
- Registration Number
- NCT00006348
- Locations
- 🇺🇸
CCOP - Scottsdale Oncology Program, Scottsdale, Arizona, United States
🇺🇸Rapid City Regional Hospital, Rapid City, South Dakota, United States
🇺🇸Altru Health Systems, Grand Forks, North Dakota, United States
Acupressure and Acustimulation Wrist Bands for the Prevention of Nausea and Vomiting Caused by Chemotherapy
- Conditions
- First Posted Date
- 2004-03-23
- Last Posted Date
- 2015-10-15
- Lead Sponsor
- Gary Morrow
- Target Recruit Count
- 700
- Registration Number
- NCT00003817
- Locations
- 🇺🇸
Hackensack University Medical Center, Hackensack, New Jersey, United States
🇺🇸University of Rochester Cancer Center, Rochester, New York, United States
Comparison of Antiemetic Drugs in Preventing Delayed Nausea After Chemotherapy in Patients With Cancer
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2015-10-15
- Lead Sponsor
- Gary Morrow
- Registration Number
- NCT00020657
- Locations
- 🇺🇸
MBCCOP - Gulf Coast, Mobile, Alabama, United States
🇺🇸CCOP - Mayo Clinic Scottsdale Oncology Program, Scottsdale, Arizona, United States
🇺🇸CCOP - Central Illinois, Decatur, Illinois, United States
Ondansetron With/Out Dexamethasone to Prevent Vomiting in Patients Receiving Radiation to the Upper Abdomen
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2020-04-03
- Lead Sponsor
- NCIC Clinical Trials Group
- Target Recruit Count
- 211
- Registration Number
- NCT00016380
- Locations
- 🇨🇦
Maisonneuve-Rosemont Hospital, Montreal, Quebec, Canada
🇨🇦Centre Hospitalier Universitaire de Quebec, Quebec City, Quebec, Canada
🇨🇦British Columbia Cancer Agency, Vancouver, British Columbia, Canada
Ondansetron for the Treatment of Methamphetamine Dependence - 1
- Conditions
- First Posted Date
- 2002-06-18
- Last Posted Date
- 2017-01-12
- Lead Sponsor
- National Institute on Drug Abuse (NIDA)
- Target Recruit Count
- 154
- Registration Number
- NCT00040053
- Locations
- 🇺🇸
South Bay Treatment Center, Chula Vista, California, United States
🇺🇸John A. Burns School of Medicine, Honolulu, Hawaii, United States
🇺🇸Powell Chemical Dependency Center, Des Moines, Iowa, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.